ArticleRheumatology international2018
Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
Article in Rheumatology international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Long-Term Safety of Anti-Interleukin-1 Medications in Children with Rheumatic Diseases: a Systematic Review.Paediatric drugs · 2025Pooled it
- The effect of canakinumab treatment on growth parameters in children with familial Mediterranean fever.Clinical rheumatology · 2024Article
- A narrative review on the role of cytokines in the pathogenesis and treatment of familial Mediterranean fever: an emphasis on pediatric cases.Frontiers in pediatrics · 2024Review
- Uveitis Associated with Monogenic Autoinflammatory Syndromes in Children.Ocular immunology and inflammation · 2023Review
- Autoinflammatory diseases and the kidney.Immunologic research · 2023Review
- Effect of interleukin-1 antagonist on growth of children with colchicine resistant or intolerant FMF.Pediatric rheumatology online journal · 2023Article
- Amyloidosis and Glomerular Diseases in Familial Mediterranean Fever.Medicina (Kaunas, Lithuania) · 2021Review
- Utilization of biotechnological drugs in rare diseases requiring the use of off-label drugs in children in TurkeyTurkish journal of medical sciences · 2021Article
- Real-Life Indications of Interleukin-1 Blocking Agents in Hereditary Recurrent Fevers: Data From the JIRcohort and a Literature Review.Frontiers in immunology · 2021Review
- The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature.Journal of inflammation research · 2020Review
- The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review.Frontiers in immunology · 2020Review
- Successful management of colchicine resistant familial Mediterranean fever patients with a standardized canakinumab treatment protocol: a case series and literature review.Rheumatology international · 2020Review
- Update on the management of colchicine resistant Familial Mediterranean Fever (FMF).Orphanet journal of rare diseases · 2019Review
- Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.Paediatric drugs · 2019Article
- Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine.European journal of rheumatology · 2019Article
- Pediatric rheumatology in Turkey.Rheumatology international · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Familial Mediterranean fever (FMF), the most common hereditary autoinflammatory disorder is characterized by recurrent episodes of fever, serositis, arthritis. The major long-term result is amyloidosis. Colchicine remains the principle of the treatment; it not only prevents the acute attacks but also prevents the long-term complications such as amyloidosis; 5-10% of the patients are unresponsive to treatment. Recently new therapeutic options as anti-interleukin 1 agents are successfully used for the patients who do not respond to colchicine treatment. In this study, we retrospectively evaluated 11 pediatric colchicine-resistant FMF patients who were treated with canakinumab. Three of the patients had amyloidosis and two had uveitis. Based on our results, we suggest that canakinumab may be a safe and effective therapy in patients who are resistant to colchicine and even in the patients with amyloidosis. We also suggest that canakinumab might be a safe option for the patients with uveitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.